SANOFI-ADR (SNY) Stock News
NASDAQ:SNY - Nasdaq - US80105N1054 - ADR - Currency: USD
SNY Latest News, Press Relases and Analysis
SANOFI-ADR (NASDAQ:SNY) – A Pharmaceutical Stock With Undervalued Potential
SANOFI-ADR (SNY) offers strong profitability, an attractive dividend, and undervalued metrics, making it a compelling choice for value investors in the pharmaceutical sector.
SANOFI-ADR (NASDAQ:SNY) – A Reliable Dividend Stock with Strong Fundamentals
SANOFI-ADR (SNY) offers a strong 4.27% dividend yield with sustainable payouts, solid profitability, and manageable debt, making it a top pick for income investors.
Stock market today: Dow, S&P 500, Nasdaq slip as US-China trade tensions flare up again
China added fuel to simmering trade tensions with the US, setting investors on guard as they turned the page on a bullish May.
Sanofi To Buy Blueprint Medicines For Up To $9.5B: Retail Sees More Acquisition Offers From European Pharma Companies
Sanofi will pay $129 per share in cash at closing, representing a 27% premium to Blueprint’s closing price on Friday of $101.35.
Mentions: BPMC
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals
Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved efficacy and safety profile.
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout
Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline. Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM), a rare immunology disease, which is characterized by the accumulation and activation of aberrant mast cells
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout
Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
/PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic...
Mentions: BPMC
Diversification Strategy Sparks Bullish Impetus in Nebius Group Stock (NBIS)
When I first invested in Nebius Group (NBIS) earlier this year, I approached it with cautious optimism—hyper-growth stocks carry inherent risk. Today, with the stock up over 50%, I remain confident and recently raised my 12-month price target to $60, implying further upside of over 50%. While its EV/Sales multiple above 50x may appear steep, it’s less relevant for a vertically integrated AI infrastructure leader positioned to capitalize on current momentum. In my view, Nebius remains one of the
Best Stock to Buy Right Now: Realty Income vs. Agree Realty
Realty Income is a net lease REIT with a lofty 5.8% dividend yield. Agree Realty is a net lease REIT with a roughly 4.1% yield. Realty Income wins on yield but falls short of Agree Realty on this key metric.
Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies
Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.
Mentions: REGN
Pharma Stock Roundup: LLY's New Deal, GSK & SNY's Pipeline Updates
LLY to acquire SiteOne for up to $1 billion. GSK's antibiotic study ends early for efficacy. MRNA loses H5 flu vaccine funding, while SNY sees mixed COPD data.
Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure
Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.
Regeneron shares slide on mixed trial data for smoker's lung drug
(Reuters) -Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition commonly called "smoker's lung" failed a late-stage trial, although it succeeded in another. Regeneron and partner Sanofi were studying the drug, which some analysts expect could bring in peak sales of as much as $5 billion, for treating chronic obstructive pulmonary disease (COPD). Investors had pinned their hopes on the drug, itepekimab, which targets a broader population, to potentially drive growth beyond Regeneron and Sanofi's blockbuster Dupixent, which is also approved for the condition, as its patent expiry looms.
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
Mentions: REGN
Economists Warn ECB to Avoid Delaying Over Last Two Rate Cuts
(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergNYC Congestion Toll Brings In $216 Million in First Four MonthsNow With Colorful Blocks, Tirana’s Pyramid Represents a Changing AlbaniaThe Economic Benefits of Paying Workers to MoveNY Wins Order Against US Funding Freeze in Congestion FightWhy Arid Cities Should Stick TogetherThe European Central Bank will lower interest rates twice more, according to a Bloomberg survey, but responde
BofA Cuts PDD Holdings (PDD) Target to $120, Maintains Hold
On May 28, PDD Holdings (NASDAQ:PDD) reported weaker quarterly results, prompting Bank of America Securities analyst Joyce Ju to lower her price target to $120 from $140 and reiterate a “Hold” rating on the shares. Ju was disappointed with a slowdown in transaction revenue growth in Q1 2025, as well as a decline in adjusted […]
TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock?
TEVA rises 12.9% in a month as investors react to mixed first-quarter results, cost-cutting plans and growing momentum in branded and biosimilar drug sales.
RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?
Recursion Pharmaceuticals and Schrodinger leverage their respective AI drug discovery platforms to potentially develop distinguished therapeutic candidates.
Sanofi, VNVC Launch Vaccine Manufacturing Facility In Vietnam, Says Report: Retail’s Positive
According to Reuters, operations at the new facility are expected to begin by the end of 2027.
Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More
NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.
Analysts Think These Stocks Could More Than Double in Value
Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.
FDA Approves GSK's Nucala for Expanded Use in COPD
GSK's Nucala wins FDA nod for COPD with eosinophilic phenotype, marking its fifth indication and strengthening its respiratory portfolio.
Vigil Neuroscience to be acquired by Sanofi for $8.00 per share
Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which Sanofi will acquire Vigil for an upfront payment of $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the
Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence
/PRNewswire/ -- Sanofi today announces the formal opening of the company's new flagship US offices, unveiling a state-of-the-art modern workplace fostering...
Vigil Neuroscience Stock Triples as Drugmaker Agrees to Acquisition by Sanofi
Vigil Neuroscience shares jumped nearly 250% Thursday after the Alzheimer's disease drug developer reached a deal to be acquired by French pharmaceutical giant Sanofi.
Better Weight Loss Stock: Amgen or Viking Therapeutics?
Amgen's weight loss candidate reported mixed phase 2 data, but the company has other weapons. Viking Therapeutics' leading anti-obesity program aced mid-stage studies, and it's not its only promising candidate. Deciding between these two stocks might come down to each investor's style, priorities, and risk tolerance.
MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot
Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.
Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout
SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's disease.
Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying
The company is working on an Alzheimer's treatment that increases the activity of TREM2, a neuroinflammation target.
Apple Brings Back Fortnite to U.S. App Store After Five-Year Absence
Apple Inc. (NASDAQ:AAPL) has authorized Fortnite’s re-entry into the US App Store, bringing an end to a five-year absence that started in 2020. The ruling comes after the court warned the firm on Monday to either allow the app or settle its conflict with Epic Games. Epic submitted Fortnite for assessment on May 9, but […]
Victoria’s Secret Uses ‘Poison Pill’ as Brett Blundy’s BBRC Increases Stake
On May 20, Australian billionaire Brett Blundy’s investment vehicle, BBRC International Private Limited, increased its stake in the lingerie manufacturer, Victoria’s Secret & Co. (NYSE:VSCO), to implement a limited-duration shareholder rights plan. According to Board Chair Donna James, the “poison pill” prevents anyone from taking over the business without paying all shareholders a fair premium. […]